NeurogesX (NGSX) received some very good news this week when the U.S. FDA approved Qutenza for the management of postherpetic neuralgia (PHN). Management will now move forward with preparing for the commercial launch during the first half of 2010.

Securing reimbursement and hiring the sales force remain the next biggest hurdles for the company. However, with approval now complete and the financial position solid ($57 million in cash on hand), we remain very position on the NeurogesX story.

We recommend accumulating the stock at today’s level up to $12 per share. Our rating is Outperform.

Zacks Investment Research

Similar Posts: NeurogesX Inc | NGSX | Drug Manufacturers - Other | Healthcare

RSS feeds: NeurogesX Inc | NGSX | Drug Manufacturers - Other | Healthcare |

Other Posts by vitalstocks | RSS Feed for this author